News &
Media
-
Weed Week: Cannabis-feed for chickens and cannabis campaigner nabs Queen’s Birthday honour
View MoreThe company recently reported significant development in the preclinical research of its lead asset program, NTI164 – a proprietary cannabis strain that contains high levels of unique minor cannabinoids and less than 0.3% THC, exclusively licensed from Dolce Cann Global.
-
Neurotech International reports positive preclinical data from combination study
View MoreNeurotech International (ASX:NTI) has reported positive preclinical research demonstrating that its NTI164 can improve diclofenac efficacy at low doses.
-
ASX Health Stocks: Neurotech says its cannabis strain works well when combined with Diclofenac
View MoreNeurotech International (ASX:NTI) has today reported significant development in the preclinical research of its lead asset program, NTI164.
-
Neurotech International (ASX:NTI) sees preclinical success with combination therapies
View MoreNeurotech International (NTI) has reported preclinical research demonstrating its proprietary cannabis strain can improve Diclofenac efficacy at low doses.
-
Neurotech International (ASX: NTI) – Webinar Presentation
View MoreDr. Alexandra Andrews – CEO – Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of its proprietary cannabis strains.
-
Webinar Recap – NTI, MHK, RPM & ESK
View More -
Australia’s top 20 cannabis companies
View MoreA report from FreshLeaf Analytics forecasts Australian medicinal cannabis sales of $423 million for 2022, up from an estimated $230 million in 2021. As prices for practically everything rose last year, medicinal cannabis prices went down on average, opening up more budgets to treatment.
-
Neurotech International (ASX:NTI) appoints Alexandra Andrews as CEO
View MoreDr Andrews has experience in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments.
She has a Doctor of Philosophy in Neuroscience from the University of Western Australia.
-
Neurotech International Phase I/II Autism Results Due this Quarter
View MoreIn July last year Neurotech International (NTI: $0.05) acquired a license from Dolce CannGroup for access to specific proprietary strains of cannabis for the potential treatment of various neurological conditions.